deaths (OS)

mGC or mGEJC - L1 - PDL1 positive metastatic/advanced mGC or mGEJC mGC or mGEJC - 1st line (L1) mGC or mGEJC - L1 - PDL1 positive

versus placebo plus SoC
pembrolizumab alone vs. placebo plus SoC 1 certainty unassessable-29%
pembrolizumab plus SoC vs. placebo plus SoC 2 certainty unassessable-14%
versus Standard of Care (SoC)
pembrolizumab alone vs. Standard of Care (SoC) 1 certainty unassessable-8%